10-K · March 12, 2026
Seres Therapeutics (MCRB) positions itself as a leader in live biotherapeutics with a proprietary MbTx platform, GMP manufacturing capabilities, and multiple pipeline candidates (SER-155, SER-603, SER-147). The company…
Earnings analysis · 10-Q
MCRB earnings analysis
Filed May 5, 2026 · Our reading of the company's report
The latest report
Seres Therapeutics reported no revenue for Q1 2026, with a net loss of $19.9 million compared to a profit of $32.7 million in Q1 2025. Expenses decreased significantly to $21.3 million from $27.2 million, mainly due to…
Read full summary
Seres Therapeutics reported no revenue for Q1 2026, with a net loss of $19.9 million compared to a profit of $32.7 million in Q1 2025. Expenses decreased significantly to $21.3 million from $27.2 million, mainly due to reduced general and administrative costs, and the absence of manufacturing service costs post-transaction with Nestlé. The company is focusing on its pipeline, requiring additional funding after Q3 2026, while facing increased scrutiny on cash flow and compliance with evolving regulations.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Net Loss Decline
Reported a net loss of $19.9 million, a significant decline from a net income of $32.7 million in Q1 2025.
-
Operational Expense Reduction
Total operating expenses fell to $21.3 million from $27.2 million, primarily due to lower general and administrative costs.
-
Pipeline Focus
The company continues to advance project SER-155 despite pausing additional investment in Phase 2 studies pending funding.
-
Decreased Workforce
Announced a 30% workforce reduction as part of cost-cutting measures implemented in February 2026.
-
Sufficient Cash Until Funding Needed
Held $29.8 million in cash and cash equivalents, but anticipates the need for additional funding after Q3 2026.
-
Cash Flow Implications
Reported cash used in operations was $16.4 million for Q1 2026, indicating ongoing liquidity pressures.
What to watch
-
Substantial Doubt of Going Concern
Management noted substantial doubt about the ability to continue operations for at least 12 months based on current cash resources.
-
Dependence on Funding
Requires additional capital following Q3 2026 to fund operations and development activities.
-
Ongoing Regulatory Scrutiny
Potential changes in laws regarding pricing and marketing may adversely impact financial condition.
Management's outlook
Additional funding anticipated after Q3 2026 to support ongoing operations.
Earlier filings 4
10-Q · August 6, 2025
Seres Therapeutics reported an improved quarterly operating result: loss from continuing operations narrowed to $(19,855) for Q2 2025 versus $(26,196) in Q2 2024, and GAAP net loss per share improved to $(2.27) from…
10-Q · May 7, 2025
Seres reported Q1 2025 net income of $32,682 (thousands) and diluted EPS of $3.75, driven primarily by a $52,181 gain on the sale of the VOWST business. Operating results remain challenged: loss from operations was…
10-K · March 13, 2025
The 10-K repositions the company as a clinical-stage live-biotherapeutics developer focused on advancing SER-155 after the September 2024 sale of VOWST to Nestlé. The filing highlights strong Phase 1b Cohort 2 results…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.